Study wrapper · #1358
Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use.
Wang AL, Bach L, Leiman DA Journal of clinical gastroenterology. 2026.
DOI: 10.1097/mcg.0000000000002395PubMed: 42133868
Editor's note
A useful negative finding: GLP-1 drugs clearly slow the stomach, but this single-center case-control comparison found no measurable effect on the esophagus itself. The sample is small and the overall motility comparison landed at P=0.07, close enough to the threshold that a larger study could shift the picture. For now it supports letting patients stay on their GLP-1 through esophageal testing.
Plain-language abstract
A retrospective study of 132 patients with type 2 diabetes who underwent formal esophageal testing found no significant difference in swallowing-muscle function or reflux results between GLP-1 users (most commonly on semaglutide) and non-users.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026